Company intelligence / Profile preview

ProgenaCare

Ownership: Private
Development stage: Commercial

Overview

ProgenaCare has two main commercial products for advanced wound care. ProgenaMatrix is the first and only commercially available human keratin matrix for wound healing. revyve Antimicrobial Wound Gel uses a patented antibiofilm technology combined with PHMB in a thermo-reversible hydrogel to provide superior antimicrobial activity and promote moist wound healing environments. Both products are used clinically and have demonstrated efficacy in supporting natural healing processes and reducing infection risk in chronic and acute wounds[1][2][3][4].

Therapeutic areas: OtherDermatologyEndocrinology
Modalities: DeviceBiologic (specifically human keratin matrix)Hydrogel-based drug delivery therapy
Industry: Biotech

Drug pipeline

1 asset

ProgenaMatrix

Unknown

Partnerships

Kane Biotech Inc.

Beyond the preview

Go deeper on ProgenaCare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProgenaCare.

Explore the full profile